Caribou Prepares To Unveil Data On PD-1 Knock Out CAR-T
Also Uses Immune Cloaking
Executive Summary
Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.
You may also be interested in...
CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.
Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science
Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."